FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Indicative Announcement regarding the Registration Progress of Pharmaceutical Product of Fosun Kite Biotechnology Co., Ltd.*" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
23 June 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Stock code: 600196 Stock abbreviation: Fosun Pharma Announcement No.: Lin 2021- 095

Bond code: 143020 Bond abbreviation:17 Fosun 01

Bond code: 143422 Bond abbreviation:18 Fosun 01

Bond code: 155067 Bond abbreviation:18 Fosun 02

Bond code: 155068 Bond abbreviation:18 Fosun 03

Bond code: 175708 Bond abbreviation: 21 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Indicative Announcement regarding the Registration Progress of Pharmaceutical Product of Fosun Kite Biotechnology Co., Ltd.*

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents contained herein.

Important (definitions are the same as the text)

1. As at the date of this announcement, the Company indirectly holds 50% equity interest in Fosun Kite, and Fosun Kite is a joint venture of the Company.

2. As at the time of this announcement, the certificate of drug registration approval for the CAR-T Cell Therapy Product has yet to be received. The registration of the Product is subject to the official certificate of drug registration approval to be issued and the information contained in such registration certificate shall prevail.

3. Due to the industry characteristics of pharmaceutical products, the sale of the Product after the approval may be affected by factors including, among others, market conditions and sale channels, which will have greater uncertainty.

I. Overview

On 22 June 2021, as indicated in the public information on the website of the National Medical Products Administration ("**NMPA**") (http://www.nmpa.gov.cn), the status of marketing registration approval for the autologous CD19-directed CAR-T cell therapy Axicabtagene Ciloleucel (code FKC876, the "**Product**" or "**CAR-T Cell Therapy Product**") of Fosun Kite Biotechnology Co., Ltd.* (復星凱特生物科技有限公司) ("**Fosun Kite**", a 50% equity interest of which is held by Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.* (上海復星醫藥產業發展有限公司), a subsidiary of the Company), an investee company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**"), was updated to "the certificate of drug approval to be collected" with the approval number of "Guo Yao Zhun Zi S20210019".

II. Basic Information of the Product

The Product is produced following the technology transfer of the autologous CD19-directed CAR-T cell therapy (Yescarta®) of Kite, a Gilead company in the United States and proposed to carry out localized production in PRC (excluding Hong Kong, Macau and Taiwan). The indication for the registration application of the Product is for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Fosun Kite initiated the technology transfer of the Product from Kite and obtained technical and commercial rights in Chinese Mainland, Hong Kong SAR and Macau SAR.

III. Impact on the Listed Company and Risk Warning

1. As at the date of this announcement, the Company indirect holds 50% equity interest in Fosun Kite, and Fosun Kite is a joint venture of the Company.

2. As at the time of this announcement, the certificate of drug registration approval for the CAR-T Cell Therapy Product has yet to be received. The registration of the Product is subject to the official certificate of drug registration approval to be issued and the information contained in such registration certificate shall prevail.

3. Due to the industry characteristics of pharmaceutical products, the sale of the Product after the approval may be affected by factors including, among others, market conditions and sale channels, which will have greater uncertainty.

Investors should be aware of the investment risks.

Announcement is hereby given.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. *

23 June 2021

* for identification purposes only